Researcher Profile
Lawrence N. Shulman, MD
Associate Professor of Medicine, Harvard Medical School
Center/Program
Department
Medical Oncology/Solid Tumor Oncology
Area of Research
New Therapies for Breast Cancer and Lymphomas
Contact Information
Lawrence N. Shulman, MDDana-Farber Cancer Institute
44 Binney Street
Dana 1608
Boston, MA 02115
Office phone: (617) 632-2277
Fax: (617) 632-2260
E-mail: lawrence_shulman@dfci.harvard.edu
Preferred contact method: appointment phone
Research
Dr. Shulman is involved in the development and testing of new therapies for patients with breast cancer. At the national level, he is a member of the Cancer and Leukemia Group B Breast Core Committee. He is the national cochair of a recently completed adjuvant chemotherapy study comparing cyclophosphamide and doxorubicin with doxorubicin and docetaxel for women with primary breast cancer and 0 to 3 positive axillary nodes.
He is the national principal investigator for the current node-negative adjuvant breast cancer trial which is a 2 x 2 factorial design comparing cyclophosphamide and doxorubicin with single-agent paclitaxel given as either standard or long duration therapy. This protocol is active throughout the United States with a planned accrual of 4,646 patients. In addition, Dr. Shulman is interested in the development of new biological targeted therapies and is actively engaged with several pharmaceutical companies in the development of these promising agents.
Biography
Dr. Shulman received his MD from Harvard Medical School in 1975 and trained in hematology-oncology at Beth Israel Hospital in Boston. He served as clinical director of hematology-oncology at Brigham and Women's Hospital, which joined its adult oncology program with that of DFCI in 1996. He is currently chief medical officer and senior vice president for Medical Affairs at DFCI, and is actively involved in clinical research in breast cancer.
Select Publications
- Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:1934-50.
- Bellon JR, Shulman LN, Come SE, Li Z, Gelman RS, Silver BJ, Harris JR, Recht A. A prospective study of concurrent cyclophosphamide, methotrexate, 5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer 2004;100:1358-64.
- McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004;27:485-8.
- Canellos GP, Gollup J, Neuberg D, Mauch P, Shulman, LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003;14:268-72.
- Ponte PR, Conlin G, Conway JB, Grant S, Medeiros C, Nies J, Shulman L, Branowicki P, Conley K. Making patient-centered care come alive: achieving full integration of the patient's perspective. J Nurs Adm 2003;33:82-90.
